P00749 (UROK_HUMAN) Homo sapiens (Human)

Urokinase-type plasminogen activator UniProtKBInterProSTRINGInteractive Modelling

431 aa; Sequence (Fasta) ; (Isoform 2)

Available Structures

155 Experimental Structures

DescriptionPDB IDOligo-stateRangeLigands
Elaborate Manifold of Short Hydrogen Bond Arrays Mediating Binding of Active Site-Directed Serine P…
1o3p
 Heteromer
164-424
2×CIT; 1×655;
Assess
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…
1gjb
 Heteromer
164-424
2×CIT; 1×130;
Assess
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1…
1o5b
 Heteromer
164-423
1×ESI; 3×CIT;
Assess
Low molecular weigth human Urokinase type Plasminogen activator 2-[6-(3'-Aminomethyl-biphenyl-3-ylo…
3ig6
 Heteromer
168-423
1×438;
Assess
Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inh…
7zrt
 Heteromer
179-425
2×SO4; 2×PEG; 3×EDO; 1×1PE; 1×ZBR;
Assess
Crystal Structure of a Michaelis Complex between Plasminogen Activator Inhibitor-1 and Urokinase-ty…
3pb1
 Heteromer
P05121; 		179-425
2×SO4;
Assess
Crystal structure of uPA in complex with a camelid-derived antibody fragment
5hgg
 Heteromer
179-424
5×GOL; 2×SO4; 3×TWN; 1×MES;
Assess
Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18…
4jk5
 Heteromer
179-423
4×SO4; 2×CL; 1×P6G; 1×ZBR;
Assess
Human urokinase-type Plasminogen Activator (uPA) in complex with a bicyclic peptide inhibitor (UK18…
4jk6
 Heteromer
179-423
4×SO4; 1×CL; 1×P6G; 1×ZBR;
Assess
The crystal structure of uPA in complex with the Fab fragment of mAb-112
4dw2
 Heteromer
184-424
1×SO4;
Assess
Structure of urokinase receptor, urokinase and vitronectin complex
3bt1
 Heteromer
P04004; Q03405; 		28-152
1×NAG; 2×NAG;
Assess
Structure of anti-uPAR Fab ATN-658 in complex with uPAR
4k24
 Heteromer
P04004; Q03405; 		28-152
2×NAG; 1×MAN; 1×NAG;
Assess
Structure of urokinase receptor, urokinase and vitronectin complex
3bt2
 Heteromer
P04004; Q03405; 		29-152
2×NAG; 1×NAG;
Assess
Crystal structure of stabilized human uPAR mutant in complex with ATF
3u73
 Heteromer
Q03405; 		30-152
1×NAG; 2×NAG;
Assess
Structure of Human Urokinase Plasminogen Activator in Complex with Urokinase Receptor and an anti-u…
2fd6
 Heteromer
Q03405; Q52L64; Q924Q0; 		31-152
1×NAG; 1×NAG; 1×SO4; 3×ETX; 2×EDO; 1×PGE; 1×NDG; 1×PG4;
Assess
Crystal structure of ATF-urokinase receptor complex
2i9b
 Heteromer
Q03405; 		31-152
1×NAG; 1×SO4;
Assess
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…
1gja
homo-2-mer160-423
2×CIT; 1×135;
Assess
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…
1gj8
homo-2-mer160-423
2×CIT; 1×133;
Assess
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…
1gjd
homo-2-mer160-423
2×CIT; 1×136;
Assess
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI…
1c5y
homo-2-mer164-426
3×FLC; 1×ESP;
Assess
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI…
1c5x
homo-2-mer164-426
3×FLC; 1×ESI;
Assess
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI…
1c5w
homo-2-mer164-426
3×FLC; 1×ESI;
Assess
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…
1gj7
homo-2-mer164-424
2×CIT; 1×132;
Assess
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1…
1o5c
homo-2-mer164-424
1×CR9; 2×CIT;
Assess
Dissecting and Designing Inhibitor Selectivity Determinants at the S1 site Using an Artificial Ala1…
1o5a
homo-2-mer164-424
1×696; 1×CIT;
Assess
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…
1gjc
homo-2-mer164-424
2×CIT; 1×130;
Assess
ENGINEERING INHIBITORS HIGHLY SELECTIVE FOR THE S1 SITES OF SER190 TRYPSIN-LIKE SERINE PROTEASE DRU…
1gj9
homo-2-mer164-424
2×CIT; 1×134;
Assess
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK …
1gi8
homo-2-mer164-423
2×CIT; 1×BMZ;
Assess
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK …
1gi7
homo-2-mer164-423
1×120; 2×CIT;
Assess
A NOVEL SERINE PROTEASE INHIBITION MOTIF INVOLVING A MULTI-CENTERED SHORT HYDROGEN BONDING NETWORK …
1gi9
homo-2-mer164-423
1×123; 2×CIT;
Assess
STRUCTURAL BASIS FOR SELECTIVITY OF A SMALL MOLECULE, S1-BINDING, SUB-MICROMOLAR INHIBITOR OF UROKI…
1c5z
homo-2-mer164-423
3×FLC; 1×BEN;
Assess
LMW U-PA Structure complexed with EGRCMK (GLU-GLY-ARG Chloromethyl Ketone)
1lmw
homo-2-mer168-426
1×0GJ;
Assess
UROKINASE-TYPE PLASMINOGEN ACTIVATOR INHIBITOR COMPLEX WITH A 1-(7- SULPHOAMIDOISOQUINOLINYL)GUANID…
2vnt
monomer165-427
1×QGG;
Assess
Tranexamic Acid is an Active Site Inhibitor of Urokinase Plasminogen Activator
6nmb
monomer166-424
1×NO3; 1×AMH;
Assess
Crystal structure of complex of urokinase and a upain-1 variant(W3F) in pH7.4 condition
6xvd
monomer179-426
Assess
The crystal structure of uPA complex with peptide inhibitor MH027 at pH4.6
3ox7
monomer179-426
1×SO4; 1×PG4;
Assess
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…
2vip
monomer179-426
1×ACT; 1×SO4; 1×L1R;
Assess
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…
2viv
monomer179-426
1×ACT; 1×VG2;
Assess
Crystal structure of uPA in complex with upain-2-3-W3A
5wxp
monomer179-426
1×ALA; 1×CYS;
Assess
Crystal structure of uPA in complex with 6-amidino-2-naphthol
7vm6
monomer179-426
1×7R8; 1×SO4; 1×PGE;
Assess
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…
2vio
monomer179-426
1×ACT; 1×L1O;
Assess
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…
2vin
monomer179-426
1×ACT; 1×SO4; 1×505;
Assess
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…
2viq
monomer179-426
1×ACT; 1×D55;
Assess
Synthesis of a Weak Basic uPA Inhibitor and Crystal Structure of Complex with uPA
4h42
monomer179-426
1×11E; 1×PG6;
Assess
Fragment-Based Discovery of Mexiletine Derivatives as Orally Bioavailable Inhibitors of Urokinase-T…
2viw
monomer179-426
1×ACT; 1×D56;
Assess
The crystal structure of uPA complex with peptide inhibitor MH027 at pH7.4
3oy5
monomer179-426
1×SO4;
Assess
The crystal structure of upain-1-W3A in complex with uPA at pH7.4
4zko
monomer179-425
1×SO4; 1×P6G;
Assess
The complex crystal Structure of Urokianse and 2-Aminobenzothiazole
3mhw
monomer179-425
1×SO4; 1×ABV;
Assess
The crystal structure of mupain-1-17 in complex with murinised human uPA at pH4.6
4x1p
monomer179-425
2×SO4; 2×PGE; 1×MRZ;
Assess
Crystal structure of human Urokinase-type plasminogen activator in complex with bicycle peptide inh…
7zrr
monomer179-425
1×1PE; 2×EDO; 1×NH2; 1×ZBR;
Assess
Crystal structure of complex of urokinase and a upain-1 variant(W3A) in pH4.6 condition
3m61
monomer179-425
Assess
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN INHIBITOR COMPLEX
1ejn
monomer179-425
1×SO4; 1×AGB;
Assess
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-BENZAMIDINE COMPLEX
1f5k
monomer179-425
2×SO4; 1×BEN;
Assess
The crystal structure of mupain-1-16 in complex with murinised human uPA at pH7.4
4x1n
monomer179-425
1×MRZ;
Assess
Urokinase type plasminogen activator
1w0z
monomer179-425
1×SI1; 2×SO4;
Assess
The crystal structure of mupain-1--16-IG in complex with murinised human uPA at pH7.4
4zhm
monomer179-425
1×MRZ;
Assess
Urokinase Plasminogen Activator B-Chain-JT463 Complex
1vja
monomer179-425
2×SO4; 1×7IN;
Assess
UROKINASE TYPE PLASMINOGEN ACTIVATOR
1w13
monomer179-425
1×SM1; 2×SO4;
Assess
Urokinase type plasminogen activator
1w10
monomer179-425
1×SJ1; 2×SO4;
Assess
UROKINASE TYPE PLASMINOGEN ACTIVATOR
1w11
monomer179-425
2×SO4; 1×SK1;
Assess
Urokinase plasminogen activator B-chain-GPPE complex
2r2w
monomer179-425
1×SO4; 1×4PG;
Assess
The crystal structure of mupain-1-IG in complex with murinised human uPA at pH7.4
4zhl
monomer179-425
Assess
The crystal structure of mupain-1-17 in complex with murinised human uPA
4x0w
monomer179-425
1×MRZ; 1×SO4;
Assess
The crystal structure of mupain-1-12 in complex with murinised human uPA at pH7.4
4x1r
monomer179-425
1×PL0;
Assess
UROKINASE TYPE PLASMINOGEN ACTIVATOR
1w14
monomer179-425
2×SO4; 1×SH1;
Assess
The crystal structure of mupain-1 in complex with murinised human uPA at pH7.4
4x1q
monomer179-425
Assess
The crystal structure of uPA complex with peptide inhibitor MH036 at pH4.6
3oy6
monomer179-425
Assess
Urokinase Plasminogen Activator B-Chain-JT464 Complex
1vj9
monomer179-425
2×SO4; 1×5IN;
Assess
UROKINASE TYPE PLASMINOGEN ACTIVATOR
1w12
monomer179-425
1×SL1;
Assess
Urokinase Plasminogen Activator B-Chain-J435 Complex
1sc8
monomer179-425
2×SO4; 1×2IN;
Assess
UROKINASE PLASMINOGEN ACTIVATOR B CHAIN-UKI-1D COMPLEX
1f92
monomer179-425
2×SO4; 1×UKP;
Assess
The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH4.6
5yc6
monomer179-424
1×PZH; 1×SO4; 2×PGE;
Assess
The crystal structure of upain-1-W3A in complex with uPA at pH9.0
4zkr
monomer179-424
1×SO4; 1×P6G;
Assess
The crystal structure of upain-1-W3A in complex with uPA at pH5.5
4zkn
monomer179-424
1×SO4; 2×PG4;
Assess
Crystal structure of uPA in complex with upain-2-2
5wxf
monomer179-424
1×SO4;
Assess
Structure of PAItrap, an uPA mutant
4xsk
monomer179-424
2×SO4; 2×PGE; 2×GOL;
Assess
Crystal Structure of the Urokinase
4fuh
monomer179-424
1×1U2; 4×SO4; 1×ACT; 7×GOL;
Assess
Crystal Structure of the Urokinase
4fu9
monomer179-424
3×SO4; 1×SIN; 6×GOL; 2×ACT; 1×675;
Assess
Crystal structure of uPA in complex with upain-2-2-W3A
5wxo
monomer179-424
Assess
uPA-HMA
5za7
monomer179-424
1×HMX; 1×SO4;
Assess
Crystal Structure of the Urokinase
4fuc
monomer179-424
1×239; 1×SIN; 4×SO4; 1×ACT; 8×GOL;
Assess
uPA-6F-HMA
5zae
monomer179-424
1×EAU; 1×SO4;
Assess
Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-carbamimidoyl-6-(furan-2-y…
6jyq
monomer179-424
1×EAU; 1×SO4;
Assess
Crystal Structure of the Urokinase
4fug
monomer179-424
1×9UP; 4×SO4; 2×GOL; 2×ACT;
Assess
The crystal structure of upain-1-W3A in complex with inactive uPA (uPA-S195A) at pH7.4
4zks
monomer179-424
Assess
Crystal Structure of the Urokinase
4fub
monomer179-424
1×4UP; 1×SO4; 1×SIN; 6×GOL; 1×15P; 5×ACT;
Assess
The crystal structure of mupain-1-16-D9A in complex with murinised human uPA at pH7.4
4x1s
monomer179-424
1×MRZ;
Assess
The crystal structure of human urokinase-type plasminogen activator catalytic domain
4dva
monomer179-424
2×SO4; 2×P6G;
Assess
Crystal structure of uPA in complex with 4-guanidinobenzoic acid
7vm5
monomer179-424
1×PGE; 1×GBS;
Assess
Crystal Structure of the Urokinase
4fu7
monomer179-424
3×SO4; 1×ACT; 1×1UP;
Assess
Crystal Structure of the Urokinase
4fud
monomer179-424
1×6UP; 3×SIN; 4×SO4; 1×NA;
Assess
Crystal Structure of the Urokinase
4fue
monomer179-424
1×7UP; 1×SIN; 2×SO4; 3×GOL; 2×ACT;
Assess
Crystal Structure of the Urokinase
4fuf
monomer179-424
1×8UP; 1×SIN; 3×SO4; 4×GOL; 3×ACT;
Assess
Crystal Structure of the Urokinase
4fui
monomer179-424
1×UI3; 3×SO4; 4×GOL; 1×NA; 1×SIN;
Assess
The crystal structure of uPA in complex with 4-Bromobenzylamirne at pH7.4
5yc7
monomer179-424
1×PZH; 1×SO4;
Assess
The complex crystal Structure of Urokianse and 5-nitro-1H-indole-2-amidine
3mwi
monomer179-424
1×B25; 2×SO4;
Assess
Crystal Structure of the Urokinase
4fuj
monomer179-424
1×1U9; 1×SIN; 2×SO4; 2×ACT; 3×GOL;
Assess
New Pharmacophore for Serine Protease Inhibition Revealed by Crystal Structure of Human Urokinase-t…
2nwn
monomer179-424
Assess
Crystal Structure of the Urokinase
4fu8
monomer179-424
1×2UP; 2×ACT; 1×SIN; 4×SO4;
Assess
Crystal structure of uPA_H99Y in complex with 3-azanyl-5-(azepan-1-yl)-N-[bis(azanyl)methylidene]-6…
6jyp
monomer179-424
1×HMX; 1×SO4;
Assess
Crystal structure of uPA in complex with S2444
5wxs
monomer179-424
1×7YF;
Assess
Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic …
3khv
monomer179-424
1×4AL; 1×SO4; 1×PGE;
Assess
The Crystal Structures of 2-Aminobenzothiazole-based Inhibitors in Complexes with Urokinase-type Pl…
3kid
monomer179-424
1×2BS;
Assess
Crystal structure of uPA in complex with quercetin
5xg4
monomer179-424
1×QUE; 1×PG6;
Assess
The crystal structure of uPA in complex with 4-Iodobenzylamine at pH7.4
5z1c
monomer179-423
1×ZXI;
Assess
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q) in com…
2o8t
monomer179-423
2×SO4; 2×1PE; 1×PEG;
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK7…
4mnw
monomer179-423
2×SO4; 5×GOL; 1×ACT; 1×ZBR;
Assess
Human urokinase-type plasminogen activator uPA in complex with the two-disulfide bridge peptide UK5…
4gly
monomer179-423
4×SO4; 2×NA; 3×CL; 1×P6G; 1×GOL;
Assess
Substituted 2-Naphthamidine inhibitors of urokinase
1owe
monomer179-423
3×SO4; 1×675;
Assess
Substituted 2-Naphthamidine Inhibitors of Urokinase
1owh
monomer179-423
3×SO4; 1×239;
Assess
uPA-BB2-50F
5za9
monomer179-423
1×50I;
Assess
Crystal structure of uPA in complex with 3,5-bis(azanyl)-6-(1-benzofuran-2-yl)-N-carbamimidoyl-pyra…
6ag9
monomer179-423
1×9XF; 1×SO4;
Assess
uPA-31F
5zaj
monomer179-423
1×32I;
Assess
uPA-BB2-28F
5zaf
monomer179-423
1×28I;
Assess
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) …
2o8u
monomer179-423
1×SO4; 2×BEN; 1×PG4; 1×PEG;
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK9…
4mny
monomer179-423
2×SO4; 2×ACT; 2×GOL; 1×29O;
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…
4os6
monomer179-423
2×SO4; 1×ACT;
Assess
Crystal structure of uPA in complex with upain-2-4-W3A
5wxr
monomer179-423
Assess
uPA-HMA
6ag2
monomer179-423
1×9X9; 1×SO4;
Assess
Crystal structure of uPA in complex with upain-2-4
5wxq
monomer179-423
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…
4os2
monomer179-423
2×SO4; 2×ACT;
Assess
Crystal structure of bicyclic peptide UK729 bound as an acyl-enzyme intermediate to urokinase-type …
4mnv
monomer179-423
1×SO4; 2×ACT; 1×ZBR; 1×GOL;
Assess
Substituted 2-Naphthamidine Inhibitors of Urokinase
1sqo
monomer179-423
3×SO4; 1×UI2;
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK8…
4mnx
monomer179-423
2×SO4; 1×GOL; 1×29N;
Assess
Crystal Structure and Binding Epitopes of Urokinase-type Plasminogen Activator (C122A/N145Q/S195A) …
2o8w
monomer179-423
1×SO4; 1×PG4; 1×PL0;
Assess
Crystal structure of inactive uPA in complex with nafamostat
7vm7
monomer179-423
1×7RF;
Assess
uPA-NU-09F
5zc5
monomer179-423
1×09I;
Assess
Substituted 2-Naphthamidine Inhibitors of Urokinase
1sqt
monomer179-423
1×UI3;
Assess
Potent and selective bicyclic peptide inhibitor (UK18) of human urokinase-type plasminogen activato…
3qn7
monomer179-423
1×ZBR;
Assess
uPA-BB2-27F
5za8
monomer179-423
1×27I;
Assess
The crystal structure of uPA in complex with HMA-55F
6ag7
monomer179-423
1×H55;
Assess
uPA-BB2-94F
5zag
monomer179-423
1×94I;
Assess
Substituted 2-Naphthamidine Inhibitors of Urokinase
1sqa
monomer179-423
3×SO4; 1×UI1;
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…
4os7
monomer179-423
3×SO4; 1×ACT; 1×GOL;
Assess
Crystal structure of uPA in complex with cleaved camostat
7dzd
monomer179-423
1×GBS; 2×PGE;
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…
4os4
monomer179-423
2×SO4; 1×GOL; 1×ACT; 1×CL;
Assess
Crystal structure of uPA in complex with nafamostat
7vm4
monomer179-423
1×GBS; 2×PGE;
Assess
Substituted 2-Naphthamadine inhibitors of Urokinase
1u6q
monomer179-423
1×745;
Assess
Crystal structure of uPA-S195A in complex with S2444
5wxt
monomer179-423
1×7YR;
Assess
UROKINASE PLASMINOGEN ACTIVATOR B-CHAIN-AMILORIDE COMPLEX
1f5l
monomer179-423
2×SO4; 1×AMR;
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…
4os1
monomer179-423
2×SO4; 1×ACT;
Assess
Crystal structure of uPA_H99Y in complex with 31F
6l04
monomer179-423
1×32I;
Assess
Crystal structure of urokinase-type plasminogen activator (uPA) complexed with bicyclic peptide UK6…
4os5
monomer179-423
2×SO4;
Assess
Substituted 2-Naphthamidine inhibitors of urokinase
1owd
monomer179-423
1×497;
Assess
Crystal Structures of Urokinase-type Plasminogen Activator in Complex with 4-(Aminomethyl) Benzoic …
3kgp
monomer179-423
1×4AZ; 1×SO4;
Assess
Crystal structure of uPA in complex with 3,5-bis(azanyl)-N-carbamimidoyl-6-(2,4-dimethoxypyrimidin-…
6ag3
monomer179-423
1×9XC;
Assess
Crystal structure of uPA_H99Y in complex with 50F
6l05
monomer179-423
1×50I;
Assess
Substituted 2-Naphthamidine Inhibitors of Urokinase
1owk
monomer179-423
1×303;
Assess
Substituted 2-Naphthamidine Inhibitors of Urokinase
1owi
monomer179-423
1×426;
Assess
uPA-BB2-30F
5zah
monomer179-423
1×30I;
Assess
Crystal structure of human microurokinase in complex with 2-amino-5-hydroxy-benzimidazole
1fv9
monomer179-423
1×SO4; 1×172;
Assess
Substituted 2-Naphthamidine Inhibitors of Urokinase
1owj
monomer179-423
1×155;
Assess
SOLUTION STRUCTURE OF THE AMINO TERMINAL FRAGMENT OF UROKINASE-TYPE PLASMINOGEN ACTIVATOR
1urk
monomer26-155
1×FUC;
Assess
Crystal structure of the free aminoterminal fragment of urokinase type plasminogen activator (ATF)
2i9a
monomer30-152
Assess
SEQUENTIAL 1H NMR ASSIGNMENTS AND SECONDARY STRUCTURE OF THE KRINGLE DOMAIN FROM UROKINASE
1kdu
monomer69-153
Assess

4 SWISS-MODEL models

TemplateOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
2vnt.3.Amonomer0.83166-426
1×QGG;99.64
Assess
3laq.1.Amonomer0.6728-151
71.43
Assess
5edm.1.Amonomer0.6069-428
29.48
Assess
1urk.1.Amonomer0.5427-153
99.21
Assess

5 SWISS-MODEL models built on isoform sequence

TemplateIsoformOligo-stateQMEANDisCoRangeLigandsTrg-Tpl Seq id (%)
Isoform 22vnt.3.Amonomer0.83149-409
1×QGG;99.64
Assess
Isoform 23bt2.2.Amonomer0.6812-135
97.60
Assess
Isoform 21urk.1.Amonomer0.5912-136
98.40
Assess
Isoform 24nzq.1.Amonomer0.5712-409
28.35
Assess
Isoform 25edk.1.Amonomer0.5512-411
28.20
Assess